Research Topics
| Chaitanya R DivgiSummaryAffiliation: University of Pennsylvania Country: USA Publications
| Collaborators
|
Detail Information
Publications
Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trialChaitanya R Divgi
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Lancet Oncol 8:304-10. 2007..We aimed to assess whether iodine-124-labelled antibody chimeric G250 ((124)I-cG250) PET predicts clear-cell renal carcinoma, the most common and aggressive renal tumour...- The use of positron-emission tomography in the diagnosis of tumour phenotypeChaitanya Divgi
University of Pennsylvania, Philadelphia, PA 19104, USA
BJU Int 101:36-8. 2008 - Instant gratification must waitChaitanya Divgi
Nuclear Medicine and Clinical Molecular Imaging, University of Pennsylvania, Philadelphia, PA 19104, USA
Eur J Nucl Med Mol Imaging 33:979-80. 2006 
Molecular imaging of pulmonary cancer and inflammationChaitanya R Divgi
Nuclear Medicine Clinical Molecular Imaging, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
Proc Am Thorac Soc 6:464-8. 2009..PET and SPECT imaging with other radiotracers of interest will also be reviewed. Future directions in PET imaging of pulmonary pathophysiology will also be explored...- Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapyNeeta Pandit-Taskar
Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Nucl Med 49:1066-74. 2008..An analysis was performed to assess lesion detectability by (111)In-J591 gamma-camera imaging compared with standard imaging methods and the effect of increasing antibody mass on lesion detectability, biodistribution, and dosimetry... - 124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PETJoseph A O'Donoghue
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
J Nucl Med 52:1878-85. 2011..The primary aim of this analysis was to examine the quantitative features of antibody-antigen interactions in tumors and normal tissue after parenteral administration of antitumor antibodies to human patients... - Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancerMichael J Morris
Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Clin Oncol 27:2436-42. 2009..To build on this strategy and fully integrate a repetitively dosed bone-seeking radiopharmaceutical into a contemporary chemotherapy regimen, we conducted a phase I study of docetaxel and samarium-153 ((153)Sm) lexidronam... - Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumorsMichael J Morris
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Clin Cancer Res 13:2707-13. 2007..This phase I trial tested the hypothesis that J591 could be used as a vascular targeting platform for patients with nonprostate solid tumors... - (124)I-huA33 antibody PET of colorectal cancerJorge A Carrasquillo
Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Nucl Med 52:1173-80. 2011..We also determined the biodistribution of (124)I-huA33 when a large dose of human intravenous IgG (IVIG) was administered to manipulate the Fc receptor or when (124)I-huA33 was given via hepatic arterial infusion (HAI)... 
Correlation of in vivo and in vitro measures of carbonic anhydrase IX antigen expression in renal masses using antibody 124I-cG250Daniel A Pryma
Division of Nuclear Medicine and Clinical Molecular Imaging, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
J Nucl Med 52:535-40. 2011....- Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancerMichael J Morris
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Clin Cancer Res 11:7454-61. 2005..The relationship among dose, safety, pharmacokinetics, and antibody-dependent cellular cytotoxicity (ADCC) activation for unlabeled J591 has not been explored... - Bone marrow dosimetry using 124I-PETJazmin Schwartz
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Nucl Med 53:615-21. 2012.... - Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancerChaitanya R Divgi
Nuclear Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Nucl Med 45:1412-21. 2004..This trial was performed to determine the maximum tolerated whole-body radiation-absorbed dose of fractionated (131)I-cG250... - Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphomaFabio M Iwamoto
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer 110:2528-34. 2007..The blood-brain barrier makes many agents used in systemic lymphomas ineffective in CNS lymphomas. The objective of this study was to determine whether intravenous radioimmunotherapy using anti-CD20 antibody can be delivered to PCNSL... - Molecular imaging of renal cell carcinomaRodolfo Perini
Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19105, USA
Urol Clin North Am 35:605-11; vi. 2008..This article discusses the evolving role of molecular imaging in the evaluation of renal cancer, including current and future applications... - Dosimetry of 11C-carfentanil, a micro-opioid receptor imaging agentAndrew B Newberg
Department of Radiology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Nucl Med Commun 30:314-8. 2009..The study was conducted within a regulatory framework that required its pharmacological safety to be assessed simultaneously... - Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastomaCameron J Koch
Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Eur J Nucl Med Mol Imaging 37:2048-59. 2010.... - Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemiaTodd L Rosenblat
Department of Medicine and the Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Clin Cancer Res 16:5303-11. 2010..This phase I/II trial was conducted to determine the maximum tolerated dose (MTD) and antileukemic effects of (213)Bi-lintuzumab, the first targeted α-emitter, after partially cytoreductive chemotherapy... - Radiopharmaceutical chemistry with iodine-124: a non-standard radiohalogen for positron emission tomographyAnn Marie Chacko
Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA
Med Chem 7:395-412. 2011..The review will conclude by highlighting promising future directions in using (124)I as a positron emitter in PET radiochemistry and molecular imaging... - Non-invasive assessment of tumor neovasculature: techniques and clinical applicationsRodolfo Perini
Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
Cancer Metastasis Rev 27:615-30. 2008.... - I-123 MIBG scan of metastatic neuroblastoma mimicking a bone scanGregory Ravizzini
Department of Radiology, Nuclear Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Clin Nucl Med 31:558-60. 2006 - Radiopharmaceutical therapy for palliation of bone pain from osseous metastasesNeeta Pandit-Taskar
Nuclear Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Nucl Med 45:1358-65. 2004..This article illustrates the salient features of these radiopharmaceuticals, including the approved dose, method of administration, and indications for use. We conclude with recommended guidelines for therapy and follow-up... - New strategies in radioimmunotherapy for lymphomaNeeta Pandit-Taskar
Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Curr Oncol Rep 5:364-71. 2003..This review highlights features of radioimmunotherapy that are relevant to non-Hodgkin's lymphoma, focusing on the two anti-CD20 antibodies... - Organ and fetal absorbed dose estimates from 99mTc-sulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patientsNeeta Pandit-Taskar
Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
J Nucl Med 47:1202-8. 2006..Calculations using actual patient population characteristics resulted in lower organ dose estimates than more conservative reference models... - Imaging: staging and evaluation of lymphoma using nuclear medicineChaitanya Divgi
Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Semin Oncol 32:S11-8. 2005..This article examines the role of the different imaging techniques available and the use of these techniques in the staging and evaluation of patients with Hodgkin's and non-Hodgkin's lymphoma... - Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trialChaitanya R Divgi
Columbia University, New York, NY 10032, USA
J Clin Oncol 31:187-94. 2013..A clinical study to characterize renal masses with positron emission tomography/computed tomography (PET/CT) was undertaken... - Optimizing prostate cancer treatment by combining local radiation therapy with systemic vaccinationHoward L Kaufman
Department of Surgery, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
Clin Cancer Res 11:6757-62. 2005 - Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinismOlga T Hardy
Division of Endocrinology, The Children s Hospital of Philadelphia, 34th Street and Civic Center Boulevard, Philadelphia, Pennsylvania 19104, USA
J Clin Endocrinol Metab 92:4706-11. 2007..This study evaluated the accuracy of 18F-fluoro-l-dihydroxyphenylalanine ([18F]DOPA) positron emission tomography (PET) scans in diagnosing focal vs. diffuse disease and identifying the location of focal lesions... - Current status of therapy of solid tumorsYuliya S Jhanwar
Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
J Nucl Med 46:141S-50S. 2005..This review will describe seminal studies that have paved the way to an understanding of radioimmunotherapy in solid tumors. Finally, the authors' views of the future of this promising cancer therapy will be presented... - Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-responseGeorge Sgouros
Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Nucl Med 44:260-8. 2003.... - Targeted alpha particle immunotherapy for myeloid leukemiaJoseph G Jurcic
Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
Blood 100:1233-9. 2002..This study demonstrates the safety, feasibility, and antileukemic effects of (213)Bi-HuM195, and it is the first proof-of-concept for systemic targeted alpha particle immunotherapy in humans... - Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapyJoseph A O'Donoghue
Memorial Sloan Kettering Cancer Center and Ludwig Institute for Cancer Research, New York, NY 10021, USA
Cancer Biother Radiopharm 17:435-43. 2002..Treatment may be prescribed on the basis of administered activity or absorbed dose. An optimal definition of maximum tolerated dose will enable the clinical benefits of RIT to be maximized... - Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastomaLawrence T Dauer
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Health Phys 92:33-9. 2007.... - Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levelsLee M Krug
Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell University, New York, NY 10021, USA
J Thorac Oncol 2:947-52. 2007..A phase I trial of humanized 3S193 (hu3S193) with dosing up to 40 mg/m2 demonstrated tumor targeting without serious toxicities or the development of human anti-human antibodies... - Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan resultsPatrick G Morris
Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Clin Breast Cancer 10:33-9. 2010..A prospective clinical study was designed to explore this hypothesis. Patients and.. - Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancerMichael J Morris
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 444, New York, NY 10021, USA
Curr Oncol Rep 6:222-9. 2004..In this article, we review the rationale behind this approach, the targets being explored, the radiation sources available, and the antibodies currently under clinical development... - PET: too much of a good thing? Does the plethora of choices impact on patient management?Chaitanya Divgi
Eur J Nucl Med Mol Imaging 32:398. 2005 - Editorial: what ails solid tumor radioimmunotherapy?Chaitanya Divgi
Cancer Biother Radiopharm 21:81-4. 2006 - A performance evaluation of 90Y dose-calibrator measurements in nuclear pharmacies and clinics in the United StatesMichael K Schultz
The National Institute of Standards and Technology, Nuclear Medicine Standards Program, 100 Bureau Drive, MS 8462, Gaithersburg, MD 20899, USA
Appl Radiat Isot 66:252-60. 2008..All results were within US Nuclear Regulatory Commission conformance limits (+/-20%) for defining therapeutic misadministrations... - Active and passive immunotherapy: vaccines and antibodiesEgbert Oosterwijk
Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
BJU Int 99:1301-4. 2007 - Radioiodine imaging and treatment in thyroid disordersWei Shen Griggs
Fairfax Radiological Consultants, Fairfax, VA 22031, USA
Neuroimaging Clin N Am 18:505-15, viii. 2008..Iodine uptake also permits treatment, using I-131, of hyperthyroid disease and cancer, for which I-131 is the primary treatment... - A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablationRichard J Robbins
Endocrinology Service, Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Nucl Med 43:1482-8. 2002..During this same time period, other patients at our center were prepared for RRA by hormone withdrawal... - Action plan for emerging molecular imaging technologiesAlexander J McEwan
J Nucl Med 49:37N-40N. 2008